Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

WTO meeting on COVID vaccine rights waiver went 'very well' -chair

Published 06/05/2022, 16:26
Updated 06/05/2022, 18:45
© Reuters. FILE PHOTO: The word "COVID-19" is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration/

By Emma Farge

GENEVA (Reuters) -The first World Trade Organization meeting to discuss a draft agreement to temporarily waive intellectual property rights for COVID-19 vaccines went "very well", its chair said on Friday, although some members voiced reservations.

The WTO's 164 members on Friday discussed the "outcome document" that stems from months of negotiations between the main parties - the United States, the European Union, India and South Africa - in an effort to break an 18-month deadlock over the issue.

"It went very well and here's why I say that. No member rejected the outcome as completely unacceptable," Ambassador Lansana Gberie from Sierra Leone, who chairs the council tasked with finding an agreement on the waiver, told Reuters after the closed-door meeting.

"Most said this could be developed into a negotiating text and that's the trajectory we have to follow."

However, two Geneva trade sources said after the meeting that some delegations had said the proposal fell short since it was too narrowly focused on vaccines, echoing criticism from some civil society groups.

And while China voiced broad support for the document it also raised an objection to some of the wording that appeared to exclude it from the waiver on the basis of its global share of vaccine exports, the two sources said.

China's statement sent by its WTO mission in Geneva called the wording "an unreasonable and arbitrary criterion".

The waiver idea, proposed by India and South Africa in October 2020, is supported by the majority of members of the global trade body.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

But some wealthy countries including Britain and Switzerland have in the past raised objections on grounds that it could harm pharmaceutical research.

WTO Director-General Ngozi Okonjo-Iweala, who has been involved in brokering the talks and wants a deal by the June ministerial conference, says an agreement would be "hugely important".

The new draft deal, which has unresolved areas, must pass by consensus and any member of the organisation has the right to a veto.

One delegate described Friday's meeting as the moment the deal would "float or sink".

Privately, some delegates have said a lack of public support for the deal by the main negotiating parties has sapped confidence among other members.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.